arrow
J

John D. Isaacs

Newcastle upon Tyne Hospitals NHS Foundation Trust
H指数:88
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial
2026-01-200
OAAI
Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response

类风湿关节炎患者接受阿达木单抗治疗后,全血转录组学数据的机器学习分析可识别出反应的预测生物标志物

2025-05-260
OAAI
The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles

DESTINIES研究:一项在线德尔菲研究,旨在就赋予免疫抑制的医疗条件和程序及其各自的COVID-19风险特征建立国际共识

2025-05-010
OAAI
Patient-reported outcomes as early warning signals of flare following drug cessation in rheumatoid arthritis

患者报告结局作为药物停用后类风湿关节炎复发的早期预警信号

2025-04-280
PRE
Patient-reported outcomes as early warning signs of flare following drug cessation in rheumatoid arthritis

患者报告结局作为药物停用后类风湿关节炎复发的早期预警信号

2025-04-010
OA
Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study

监测免疫检查点抑制后的免疫失调 (MEDALLION): 观察性癌症免疫疗法队列研究的方案

2024-06-141
OAAI
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial

Abatacept治疗类风湿关节炎高危人群 (APIPPRA): 一项随机、双盲、多中心、平行、安慰剂对照、2b期临床试验

LANCET
IF88.5
2024-03-0134
OAAI